| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NEPHROGENEX Aktie jetzt für 0€ handeln |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 30,800 | +0,10 % | JEFFERIES stuft NOVO NORDISK auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat das Kursziel für Novo Nordisk von 275 auf 270 Kronen gesenkt, aber die Einstufung auf "Hold" belassen. Analyst Michael Leuchten hob am Montagabend... ► Artikel lesen | |
| AURORA CANNABIS | 2,715 | +0,18 % | Panik vor Kursbeben: Das Zittern beginnt: Reißen die Tilray-Zahlen Canopy, Aurora & Co in die Tiefe? | © Foto: adobe.stock.comIn Kürze ist es soweit - Tilray wird frische Quartalszahlen vorlegen. Den Tilray-Zahlen kann man dabei durchaus richtungsweisenden Charakter zubilligen. Entsprechend dürften sie... ► Artikel lesen | |
| CANOPY GROWTH | 0,744 | -0,67 % | Thinking About Buying Canopy Growth Stock? You May Want to Wait for This to Happen First | ||
| TILRAY BRANDS | 5,280 | +0,96 % | Top stocks to watch this week: Tilray Brands, Nike, FactSet | ||
| VERTEX PHARMACEUTICALS | 383,65 | -0,78 % | If You Invested $1000 In Vertex Pharmaceuticals Stock 15 Years Ago, You Would Have This Much Today | ||
| TAAT GLOBAL ALTERNATIVES | 0,136 | -100,00 % | TAAT Global Alternatives Inc (2): TAAT Global CEO Saxon resigns | ||
| CRONOS GROUP | 2,086 | -1,88 % | Cronos Group Inc.: Cronos Group Reports 2025 Fourth Quarter and Full-Year Results | Net revenue in Q4 2025 increased by 47% year-over-year to $44.5 million; Net revenue in FY 2025 increased by 25% year-over-year to $146.6 million Achieved record net revenue in Q4 2025 and FY 2025... ► Artikel lesen | |
| DIGICANN VENTURES | 0,004 | 0,00 % | Digicann Ventures Inc.: Digicann Ventures Announces Agreement to Extend Maturity Date for Convertible Debentures | Vancouver, British Columbia--(Newsfile Corp. - March 12, 2026) - Digicann Ventures Ltd. (CSE: DCNN.X) ("Digicann" or the "Company"), a company focused on opportunities within and outside of the... ► Artikel lesen | |
| ORGANIGRAM GLOBAL | 1,090 | -2,68 % | Organigram Global Inc.: Organigram Announces Shareholder Approval of Acquisition of Sanity Group GmbH and Results of its Annual General and Special Meeting | Organigram Global Inc. (NASDAQ: OGI) (TSX: OGI), (the "Company" or "Organigram"), is pleased to announce that the shareholders of Organigram have overwhelmingly approved the resolution required to... ► Artikel lesen | |
| GREEN THUMB INDUSTRIES | 5,125 | +4,63 % | Green Thumb Industries Reports Fourth Quarter and Full Year 2025 Results | CHICAGO and VANCOUVER, British Columbia, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Green Thumb Industries Inc. ("Green Thumb" or the "Company") (CSE: GTII) (OTCQX: GTBIF), a leading national cannabis consumer... ► Artikel lesen | |
| NOVERIS HEALTH SCIENCES | 1,170 | 0,00 % | BC Securities Commission: BCSC halts Noveris Health after incorrect FDA claim | ||
| WAYLAND GROUP | - | - | EQS-News: Berger Montague (Canada) PC: Ankündigung der Anhörung zur Genehmigung des Vergleichs - Wayland Group Corp., Scott Langille, Gerhard Müller, Paul Pathak, Eric Silver, M. Stein, John Does 1-3, Canaccord Genuity Corp. und RF Securities Clearing LP | EQS-News: Berger Montague (Canada) PC
/ Schlagwort(e): Rechtssache/Sonstiges
ANKÜNDIGUNG DER ANHÖRUNG ZUR GENEHMIGUNG DES VERGLEICHS - KURZFASSUNG - WAYLAND... ► Artikel lesen | |
| SANTHERA PHARMACEUTICALS | 16,600 | 0,00 % | Santhera Pharmaceuticals Holding AG: Full Year 2025 Trading Update | Ad hoc announcement pursuant to Art. 53 LR
AGAMREE continues to build strong commercial momentum, delivering 98% revenue growth
Pratteln, Switzerland, March 12, 2026 - Santhera Pharmaceuticals... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 56,00 | -1,75 % | Nektar Therapeutics: Data from Phase 2b REZOLVE-AD and REZOLVE-AA Studies of Rezpegaldesleukin Presented at 2026 American Academy of Dermatology Annual Meeting | Rezpegaldesleukin demonstrates statistically significant improvement in mean percent EASI improvement across both moderate and severe atopic dermatitis patients
Rezpegaldesleukin... ► Artikel lesen | |
| FILANA THERAPEUTICS | 1,489 | -1,39 % | Cassava Sciences Announces Name Change to Filana Therapeutics, Inc. | New corporate identity reflects the Company's mission to develop novel medicines to modulate filamin A and address unmet needs in treating TSC-related epilepsy Filana Therapeutics to begin trading... ► Artikel lesen |